Acrolein

CASRN 107-02-8

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (25 pp, 176 K) last updated: 06/03/2003

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
5 x10-4 Other Decreased survival NOAEL : 0.05
mg/kg-day
100 Medium/High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (25 pp, 176 K) last updated: 06/03/2003

RfC (mg/m3) System Basis PoD Composite UF Confidence
2 x10-5 Respiratory Nasal lesions LED05 (ADJ): 0.02 x1010
mg/m3
1000 Medium

Cancer Assessment


Weight of Evidence for Cancer (PDF) (25 pp, 176 K) last updated: 06/03/2003

WOE Characterization Framework for WOE Characterization
Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (US EPA, 1999)
Basis:
  • Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the potential carcinogenicity of acrolein cannot be determined because the existing data are inadequate for an assessment of human carcinogenic potential for either the oral or inhalation route of exposure. There are no adequate human studies of the carcinogenic potential of acrolein. Collectively, experimental studies provide inadequate evidence that acrolein causes cancer in laboratory animals.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (25 pp, 176 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (25 pp, 176 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.